ESR1 and breast cancer: BAF members are differentially impaired depending on the cancer type, with ER+ breast cancer primarily characterized by aberrations in the AT rich interactive domain 1A (ARID1A/BAF250A) subunit (~ 5% at the primary tumor and ~ 12% in resistant/metastatic setting) (116-118).